+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Study on Proteinase-lnhibiting Capacity of Plasma α 2-Macroglobulin in Idiopathic Nephrotic Syndrome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We studied the relationship between plasma α<sub>2</sub>-macroglobulin (α<sub>2</sub>M) and depressed cell-mediated immunity in idiopathic nephrotic syndrome (INS). Plasma α<sub>2</sub>M concentrations (μmol/l) were increased during relapses of INS; however, the proteinase inhibitory activity, measured using bacterial thermo-lysin, was significantly decreased when calculated per 1 mol of α<sub>2</sub>M, implying a reduced proteinase-inhibiting capacity of α<sub>2</sub>M. The decreased proteinase-inhibiting capacity of α<sub>2</sub>M was associated with the inhibitory activity of plasma on normal lymphocyte blastogenesis. Purified α<sub>2</sub>M, when complexed with chymotrypsin, intensively inhibited normal lymphocyte blastogenesis induced by concanavalin A, as compared with the free form of α<sub>2</sub>M. From these results it is suggested that, although the amount of α<sub>2</sub>M protein has increased in the plasma of INS patients during relapse, its binding capacity to proteinases has relatively decreased. The results of this study may provide speculation for both the well-known high plasma α<sub>2</sub>M concentrations and the immunodepres-sion, both of which have been observed in INS patients in the past few decades.

          Related collections

          Author and article information

          S. Karger AG
          18 December 2008
          : 72
          : 4
          : 512-517
          Department of Pediatrics, School of Medicine, Niigata University, Niigata, Japan
          188931 Nephron 1996;72:512–517
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article